Trials / Completed
CompletedNCT04173039
Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis
Diagnostic Value of Antibodies Against Carbamylated Proteins in Psoriatic Arthritis.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Association pour la Recherche Clinique et Immunologique · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Anti-carbamylated protein (anti-CarP) antibodies are present in approximately one-fourth of the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein antibody and who may therefore have psoriatic arthritis. The investigators hypothesized that detection of anti-CarP antibodies in serum may be useful for diagnosis of psoriatic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Serum anti-CarP antibodies detection | Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics. |
Timeline
- Start date
- 2018-08-29
- Primary completion
- 2019-04-24
- Completion
- 2019-04-24
- First posted
- 2019-11-21
- Last updated
- 2019-11-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04173039. Inclusion in this directory is not an endorsement.